Owner Management in South Korean Pharmaceutical Companies: Balancing Growth and Governance

South Korea’s pharmaceutical industry is at a pivotal moment, striving to enhance competitiveness through increased investment in new drug development. This push for innovation is juxtaposed with a long-standing challenge: the separation of corporate ownership and management, and the potential impact of owner family influence on corporate value. This article examines the advantages and disadvantages of owner management within domestic pharmaceutical companies, using Samchundang Pharmaceutical as a case study, and considers the implications for transparency and ESG (Environmental, Social, and Governance) standards.

Samchundang Pharmaceutical: A Case Study in Owner-Led Growth

Samchundang Pharmaceutical, specializing in prescription drugs, particularly ophthalmic eye drops, has experienced recent growth fueled by the development of an oral GLP-1 obesity treatment and a licensing agreement with Daiichi Sankyo Espa [1]. In January 2024, Forbes estimated Chairman Yoon Dae-in’s net worth at approximately 3 trillion won following the licensing agreement [1]. However, discrepancies between the announced financial details of the agreement and Samchundang Pharmaceutical’s explanations have sparked controversy.

Complex Governance Structure Centered on the Owner Family

Samchundang Pharmaceutical’s governance is structured to consolidate control within the owner family. The structure is anchored by Insan MTS, a 100% owned unlisted subsidiary controlled by CEO Hee-jae Yoon, the eldest son of Chairman Yoon. Insan MTS holds a significant stake in Sohwa, an intermediate holding company involved in pharmaceutical distribution and real estate rental. Sohwa, in turn, exerts influence over Samchundang Pharmaceutical and Optus Pharmaceutical, a specialized manufacturer of ophthalmic products.

Specifically, Chairman Yoon Dae-in and Insan MTS collectively control 100% of Sohwa’s shares. Sohwa holds a 30.69% stake in Samchundang Pharmaceutical, while the Yoon family collectively owns an additional 6.92% directly. Samchundang Pharmaceutical is the largest shareholder of Optus Pharmaceutical, with a 39.4% stake. This layered structure allows the Yoon family to maintain significant control across the entire group.

In 2024, Sohwa reduced its capital, and the appointment of a son-in-law as a professional manager further solidified the family’s control.

ESG Concerns and the Demand for Transparency

While owner management can provide decisive leadership and a long-term vision, Samchundang Pharmaceutical’s vertically integrated governance structure is increasingly at odds with global trends towards ESG management and governance transparency. The structure raises questions about potential conflicts of interest and the prioritization of family interests over shareholder value. Some interpret the use of unlisted companies within the structure as a strategy for succession planning.

The company did not respond to inquiries regarding plans to improve management transparency through a transition to a holding company system or simplification of its governance structure.

The Broader Context: Owner Management in the Korean Pharmaceutical Industry

Samchundang Pharmaceutical’s situation reflects a broader debate within the South Korean pharmaceutical industry regarding the role of owner management. While significant investment is required for new drug development, and strong leadership is often seen as crucial, the potential drawbacks of concentrated ownership and control are becoming increasingly apparent. Balancing the need for decisive action with the demands for transparency and accountability will be a key challenge for Korean pharmaceutical companies seeking to compete on a global scale.

The pursuit of excellence in new drug development requires a holistic approach, aiming for faster development times, better patient outcomes, and reduced costs [3]. Achieving these goals requires not only scientific innovation but also robust governance and a commitment to ethical practices.